Physician profile
James P Arthur
NPI 1588680516
$1,421.85
in general payments reported to CMS, 2019-2025
19 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $36.77 · 2021: $41.29 · 2023: $197 · 2024: $285 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $257.03 | 2019-2025 | |
| Exact Sciences Corporation | $178.02 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $156.05 | 2019-2024 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $147.16 | 2019-2025 | Breztri |
| Novo Nordisk INC | $132.01 | 2019-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.32 | 2019 | |
| Janssen Pharmaceuticals, INC | $69.75 | 2019 | |
| Astellas Pharma US INC | $67.24 | 2024-2025 | Veozah |
| Lilly USA, LLC | $50.65 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $41.93 | 2023-2024 | |
| Glaxosmithkline, LLC. | $41.77 | 2019-2023 | Shingrix |
| Stryker Corporation | $41.29 | 2021 | |
| Merck Sharp & Dohme LLC | $25.70 | 2019 | |
| Tactile Systems Technology INC | $21.33 | 2023 | Entre Plus, Flexitouch Plus |
| Insulet Corporation | $16.01 | 2023 | Omnipod |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $15.51 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.10 | 2019 | |
| Amarin Pharma, INC. | $12.84 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Arthur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.